Biography
Bruce Tomczuk has recently joined Arginetix, Inc. as their Vice-President R&D. This company is devoted to the discovery and development of cures for endothelial dysfunction ranging from orphan diseases such as pulmonary arterial hypertension (PAH) to large morbidity diseases such as atherosclerosis.
He has also formed the pharmaceutical consulting firm, Chemnomics, LLC. He brings a background in both large pharma and small startup to the table. He has a diverse knowledge of topics. In the Medicinal Chemistry field, he is knowledgeable of SBDD, FBDD, SAR and chemogenomics. In the field of Biology, he is knowledgeable of Target ID and Validation, HTS and biochemical and cellular assays. He is also experienced with pharmacology models with a special focus on Inflammatory Diseases. Furthermore, he is experienced with systems biological approaches. On two last notes, he is well versed in studies of Metabolism including early ADME and Pharmacokinetics. He has a particularly skilled with formulations in the field of Pharmaceutical Sciences. Finally, he is experienced with Early toxicology.
His professional background has included Johnson & Johnson Pharmaceutical Research & Development, where he was a Research Fellow and the Chemistry Team Leader for the Inflammation and Pulmonary Diseases Team. During 1994-2003, he was the Executive Director of Chemistry at 3-Dimensional Pharmaceuticals, Inc, where he directed the Medicinal Chemistry and Drug Metabolism groups. Prior to 3-DP, he was a Research Leader at Sterling-Winthrop and a Scientist at A.H. Robins (now Wyeth).
Bruce is an inventor of 47 patents and an author of 37 publications and 36 presentations. Over the course of his career he has transitioned 6 compounds into Early and Late-stage clinical trials. His external activities include serving on the Board of the Inflammation Research Association and the Editorial Board of Current Topics in Medicinal Chemistry. He is a seasoned professional in the management of motivated scientific teams, a skilled presenter of scientific data to upper management, and a great matrix communicator.
Please see his CV, patents, publications, and conferences for further details.
Last updated December 2008.
|
